Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00481325 · ClinicalTrials.gov registry record · Phase 2

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

A Phase 2 study of Generalized Anxiety Disorder, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
260
Enrollment target
20
Study locations

NCT00481325 is a Phase 2 study of Generalized Anxiety Disorder that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 260 participants, above the 209-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00481325, a Phase 2 study of Generalized Anxiety Disorder, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
260 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder

Conditions Studied

Generalized Anxiety Disorder

Interventions

  • DRUG placebo
  • DRUG escitalopram
  • DRUG pexacerfont

Study Locations (20)

California

  • Pacific Clinical Research Medical Group - Burbank
  • Us Clinical Research Centers, Llc - Costa Mesa
  • Pacific Institute For Medical Research, Inc. - Los Angeles
  • Affiliated Research Institute - San Diego
  • Pacific Clinical Research Medical Group - Upland

Florida

  • Meridien Research - Brooksville
  • Clinical Neuroscience Solutions - Jacksonville
  • Comprehensive Neuroscience, Inc. - St. Petersburg
  • Stedman Clinical Trials - Tampa
  • Janus Center For Psychiatric Research - West Palm Beach

Connecticut

  • University Of Connecticut Health Center - Farmington
  • Comprehensive Psychiatric Care, Pc - Norwich

Indiana

  • Indiana University School Of Medicine - Indianapolis
  • Alpine Clinic - Lafayette

Kansas

  • Cientifica, Inc. At Prairie View Inc. - Newton
  • Ctt, Inc. - Prairie Village

Arizona

  • Pivotal Research Centers - Mesa

Colorado

  • Radiant Research, Inc. - Denver

Georgia

  • Carman Research - Smyrna

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2007-07
Est. Completion 2008-03
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00481325

The ClinicalTrials.gov registry entry for NCT00481325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 209-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (24% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00481325 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00481325 about?

NCT00481325 is a clinical study titled "Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder". The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder

What is the current status of trial NCT00481325?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2007-07. Estimated completion is 2008-03.

What conditions does trial NCT00481325 study?

This clinical trial studies the following conditions: Generalized Anxiety Disorder.

What interventions are being tested in trial NCT00481325?

The interventions under investigation include: placebo (DRUG), escitalopram (DRUG), pexacerfont (DRUG).

Who is sponsoring clinical trial NCT00481325?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00481325 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Generalized Anxiety Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Generalized Anxiety Disorder

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.